{"id":"symbicort","rwe":[],"tags":[],"trials":[],"_chembl":{"chemblId":"CHEMBL1370","moleculeType":"Small molecule","molecularWeight":"430.54"},"aliases":["budesonide/formoterol","Budesonide/Formoterol","budesonide and formoterol fumarate powder for inhalation","Budesonide","Formoterol"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$36.7066/GM","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$13,398","description":"SYMBICORT 160-4.5 MCG INHALER","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Symbicort","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:06:05.683356+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:06:10.951786+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Symbicort","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:06:11.301915+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucocorticoid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:06:12.359213+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1370/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:06:12.019544+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"a645756c-c692-4bc6-a858-7e7e249561bd","title":"SYMBICORT (BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE) AEROSOL [SPORTPHARM LLC]"},"ecosystem":[],"_scrapedAt":"2026-03-28T00:10:31.327Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:06:13.844416+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT07426458","phase":"PHASE4","title":"Ventilation and Perfusion in Asthmatics","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-04","conditions":"Asthma","enrollment":40},{"nctId":"NCT07433569","phase":"PHASE1","title":"A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-05","conditions":"Asthma","enrollment":12},{"nctId":"NCT06473779","phase":"PHASE3","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Severe Asthma","enrollment":326},{"nctId":"NCT05202262","phase":"PHASE3","title":"A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-01-12","conditions":"Asthma","enrollment":645},{"nctId":"NCT07372573","phase":"NA","title":"Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2026-02-01","conditions":"Asthma (Diagnosis)","enrollment":210},{"nctId":"NCT05755906","phase":"PHASE3","title":"A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-02-27","conditions":"Asthma","enrollment":374},{"nctId":"NCT06429475","phase":"PHASE3","title":"Anti-Inflammatory Reliever South Africa","status":"RECRUITING","sponsor":"University of KwaZulu","startDate":"2024-06-06","conditions":"Asthma","enrollment":1038},{"nctId":"NCT07329946","phase":"NA","title":"Immuno-inflammatory Response of Erdosteine in COPD","status":"NOT_YET_RECRUITING","sponsor":"Pierachille Santus, MD, PhD","startDate":"2026-02-28","conditions":"COPD","enrollment":30},{"nctId":"NCT06110403","phase":"PHASE1, PHASE2","title":"Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2023-09-29","conditions":"Copd","enrollment":35},{"nctId":"NCT06027606","phase":"PHASE1","title":"Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2023-09-01","conditions":"Healthy","enrollment":81},{"nctId":"NCT07052942","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care (Full Study)","status":"RECRUITING","sponsor":"DARTNet Institute","startDate":"2025-08-01","conditions":"Asthma, Asthma Attack, Asthma Exacerbations","enrollment":3200},{"nctId":"NCT06590740","phase":"PHASE4","title":"Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-10-18","conditions":"Cough-Variant Asthma","enrollment":1000},{"nctId":"NCT05689983","phase":"PHASE1, PHASE2","title":"Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-04-01","conditions":"Asthma in Children, Nonadherence, Medication","enrollment":40},{"nctId":"NCT05111262","phase":"PHASE1, PHASE2","title":"Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2021-12-16","conditions":"Asthma, Nonadherence, Medication","enrollment":60},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":"Atopic Rhinitis, Atopic Asthma","enrollment":200},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT06895460","phase":"PHASE3","title":"A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-06-20","conditions":"Bronchial Asthma","enrollment":198},{"nctId":"NCT01167010","phase":"PHASE3","title":"A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2011-04","conditions":"Asthma","enrollment":552},{"nctId":"NCT04609878","phase":"PHASE3","title":"Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-15","conditions":"Asthma","enrollment":2274},{"nctId":"NCT06272370","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care","status":"COMPLETED","sponsor":"DARTNet Institute","startDate":"2024-02-01","conditions":"Asthma, Bronchial Diseases, Respiratory Tract Infections","enrollment":103},{"nctId":"NCT04609904","phase":"PHASE3","title":"Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-01","conditions":"Asthma","enrollment":2187},{"nctId":"NCT05831566","phase":"PHASE3","title":"Expertise Asthma COPD Program with Digital Support","status":"RECRUITING","sponsor":"Franciscus Gasthuis","startDate":"2023-01-31","conditions":"Asthma","enrollment":138},{"nctId":"NCT06597682","phase":"NA","title":"Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-03","conditions":"Post-acute Sequelae of SARS-COV-2 Infection","enrollment":632},{"nctId":"NCT03924635","phase":"PHASE4","title":"An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-01","conditions":"Airway Inflammation, Asthma","enrollment":42},{"nctId":"NCT04159519","phase":"PHASE4","title":"A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-07-27","conditions":"Asthma, Severe Eosinophilic Asthma","enrollment":170},{"nctId":"NCT03888131","phase":"PHASE3","title":"Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-07-30","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":750},{"nctId":"NCT06573164","phase":"","title":"Allergic Rhinitis With/Without Asthma: Pre- and Post-Qipian Analysis","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-01-01","conditions":"Rhinitis, Allergic, Asthma","enrollment":60},{"nctId":"NCT06571942","phase":"PHASE4","title":"Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure","status":"RECRUITING","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2023-11-15","conditions":"COPD Bronchitis, Pollution Related Respiratory Disorder","enrollment":128},{"nctId":"NCT06568445","phase":"PHASE4","title":"Maintenance at Initial Treatment With Sequential Anti-Inflammation Reliever Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-08-12","conditions":"Bronchial Asthma","enrollment":90},{"nctId":"NCT06105671","phase":"NA","title":"U-LABA/ICS Effects on Exercise Performance, Formoterol","status":"COMPLETED","sponsor":"Morten Hostrup, PhD","startDate":"2024-01-05","conditions":"Exercise Performance","enrollment":20},{"nctId":"NCT02062463","phase":"PHASE3","title":"Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-05-28","conditions":"Asthma","enrollment":485},{"nctId":"NCT01803555","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07-04","conditions":"Asthma","enrollment":605},{"nctId":"NCT04835961","phase":"","title":"AdditioN of Fixed Dose Combination (FDC) Of Budesonide/Formoterol Via Elpenhaler® Device in Greek Patients With asThma accΟrding to Standard Clinical Practice.","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2021-05-01","conditions":"Asthma","enrollment":1037},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":"Asthma","enrollment":50},{"nctId":"NCT05084222","phase":"PHASE4","title":"Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2021-11-11","conditions":"Asthma","enrollment":180},{"nctId":"NCT05322707","phase":"PHASE3","title":"BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2022-04-15","conditions":"Asthma","enrollment":1485},{"nctId":"NCT04892732","phase":"","title":"Replication of the D58 Asthma Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-10-29","conditions":"Asthma","enrollment":66581},{"nctId":"NCT04705727","phase":"PHASE3","title":"Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation","status":"TERMINATED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2021-08-23","conditions":"Asthma in Children","enrollment":102},{"nctId":"NCT03290287","phase":"","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":26839},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT03033758","phase":"","title":"Evaluation of the Effectiveness and Quality of Life With the Administration of the Fixed Combination of Budesonide Formoterol in Greek Patients With Asthma During Routine Clinical Practice.","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2017-02-02","conditions":"Asthma, Quality of Life","enrollment":980},{"nctId":"NCT03015259","phase":"PHASE3","title":"Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients","status":"COMPLETED","sponsor":"Kindeva Drug Delivery","startDate":"2016-12-29","conditions":"Asthma","enrollment":1762},{"nctId":"NCT03691961","phase":"NA","title":"Corticosteroids/β2-agonists in Hair in Asthmatic Patients (CorticHair)","status":"UNKNOWN","sponsor":"Hopital Foch","startDate":"2018-09-20","conditions":"Asthma","enrollment":24},{"nctId":"NCT04215848","phase":"PHASE3","title":"As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period","status":"COMPLETED","sponsor":"Hat Yai Medical Education Center","startDate":"2020-04-01","conditions":"Asthma","enrollment":31},{"nctId":"NCT04191434","phase":"PHASE3","title":"Efficacy and Safety of Flamboyant 125/12 Association in the Treatment of Adults With Moderate Asthma","status":"UNKNOWN","sponsor":"EMS","startDate":"2022-07-22","conditions":"Asthma","enrollment":134},{"nctId":"NCT04191447","phase":"PHASE3","title":"Efficacy and Safety of Flamboyant 200/12 Association in the Treatment of Adults With Severe Asthma","status":"UNKNOWN","sponsor":"EMS","startDate":"2022-07-22","conditions":"Asthma","enrollment":134},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT03083067","phase":"NA","title":"Salvational Intervention for Reducing AECOPD Under Severe Air Pollution","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2017-03-20","conditions":"COPD Exacerbation, Air Pollution","enrollment":402},{"nctId":"NCT04078126","phase":"PHASE3","title":"Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-09-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":35},{"nctId":"NCT02237508","phase":"PHASE1","title":"A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2014-09","conditions":"Asthma","enrollment":90},{"nctId":"NCT02631941","phase":"PHASE1","title":"Clinical Study to Evaluate Z7200 Pharmacokinetics Profile","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2016-01","conditions":"Asthma","enrollment":91},{"nctId":"NCT02227394","phase":"PHASE2","title":"Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2014-08","conditions":"Asthma, Asthma Chronic, Asthma Bronchial","enrollment":20},{"nctId":"NCT02384577","phase":"","title":"Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment","status":"COMPLETED","sponsor":"Teva Pharma GmbH","startDate":"2014-07","conditions":"Patient Satisfaction","enrollment":4034},{"nctId":"NCT01432080","phase":"PHASE2","title":"Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant","status":"TERMINATED","sponsor":"Maisonneuve-Rosemont Hospital","startDate":"2011-09","conditions":"Respiratory Tract Infections, Bronchiolitis Obliterans, Cryptogenic Organizing Pneumonia","enrollment":12},{"nctId":"NCT03468790","phase":"PHASE3","title":"Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-05-09","conditions":"Asthma, Allergic","enrollment":393},{"nctId":"NCT04663386","phase":"","title":"Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway","status":"TERMINATED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2020-12-10","conditions":"Asthma, COPD","enrollment":29},{"nctId":"NCT04179461","phase":"PHASE2","title":"Personalized Treatment Algorithms for Difficult-to-treat Asthma","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-03-16","conditions":"Asthma in Children","enrollment":21},{"nctId":"NCT04331054","phase":"PHASE3","title":"Protective Role of Inhaled Steroids for Covid-19 Infection","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-13","conditions":"Covid-19 Infection, Hospitalization in Respiratory Disease Department","enrollment":146},{"nctId":"NCT01070888","phase":"PHASE4","title":"Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma","status":"TERMINATED","sponsor":"Boston Children's Hospital","startDate":"2010-02","conditions":"Exercise Induced Asthma","enrollment":6},{"nctId":"NCT03197818","phase":"PHASE3","title":"Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-12-14","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":990},{"nctId":"NCT02465567","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-06-30","conditions":"COPD","enrollment":8588},{"nctId":"NCT01117116","phase":"NA","title":"Sub-Sensitivity to Long-Acting Bronchodilators (LABA)","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2010-03","conditions":"Asthma","enrollment":21},{"nctId":"NCT01253473","phase":"PHASE4","title":"Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2012-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":46},{"nctId":"NCT02497001","phase":"PHASE3","title":"A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-08-10","conditions":"COPD","enrollment":1902},{"nctId":"NCT04675463","phase":"NA","title":"The Effects of Inhaled Budesonide-formoterol-glycopyrronium in Moderate-to-severe COPD","status":"UNKNOWN","sponsor":"ShiYue Li","startDate":"2020-12-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":50},{"nctId":"NCT01787097","phase":"PHASE4","title":"Effect of Symbicort ® on GR in Sputum in COPD","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-01","conditions":"Chronic Obstructive Lung Disease","enrollment":31},{"nctId":"NCT04607629","phase":"PHASE3","title":"An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2018-06-20","conditions":"Bronchial Asthma","enrollment":192},{"nctId":"NCT03114969","phase":"","title":"Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":450},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT04520230","phase":"PHASE4","title":"Three Treatment of Chronic Obstructive Pulmonary Disease Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2014-10-31","conditions":"COPD","enrollment":45},{"nctId":"NCT00915538","phase":"PHASE4","title":"Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)","status":"COMPLETED","sponsor":"Western Sky Medical Research","startDate":"2009-07","conditions":"Asthma","enrollment":16},{"nctId":"NCT00413387","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-09","conditions":"Bronchial Asthma","enrollment":219},{"nctId":"NCT04494321","phase":"PHASE1","title":"A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2017-06-19","conditions":"Asthma, COPD","enrollment":99},{"nctId":"NCT02972476","phase":"PHASE4","title":"Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2016-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":158},{"nctId":"NCT03788395","phase":"PHASE4","title":"The Use of an Innovative Device for Therapeutic Adherence in Pediatric Asthma","status":"COMPLETED","sponsor":"Istituto per la Ricerca e l'Innovazione Biomedica","startDate":"2019-01-10","conditions":"Asthma","enrollment":18},{"nctId":"NCT03262012","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2016-08-09","conditions":"COPD","enrollment":416},{"nctId":"NCT04171180","phase":"PHASE4","title":"The Efficacy of Budesonide/Formoterol in Cough Variant Asthma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-01","conditions":"Cough Variant Asthma","enrollment":500},{"nctId":"NCT04331470","phase":"PHASE2, PHASE3","title":"Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19","status":"UNKNOWN","sponsor":"Fasa University of Medical Sciences","startDate":"2020-04-04","conditions":"COVID-19","enrollment":30},{"nctId":"NCT02833480","phase":"PHASE2","title":"A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2015-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":69},{"nctId":"NCT00505388","phase":"","title":"A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-07","conditions":"Bronchial Asthma","enrollment":5137},{"nctId":"NCT04208581","phase":"PHASE3","title":"Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2019-10-08","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Respiratory Failure","enrollment":372},{"nctId":"NCT02495168","phase":"PHASE3","title":"Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2017-01-13","conditions":"Asthma","enrollment":1714},{"nctId":"NCT02224157","phase":"PHASE3","title":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-28","conditions":"Asthma","enrollment":4215},{"nctId":"NCT02149199","phase":"PHASE3","title":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-07-07","conditions":"Asthma","enrollment":3850},{"nctId":"NCT00159263","phase":"NA","title":"Effect of Symbicort on GR Localisation in Asthma","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2004-11","conditions":"Asthma","enrollment":10},{"nctId":"NCT01794780","phase":"PHASE4","title":"A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-02-05","conditions":"COPD","enrollment":2229},{"nctId":"NCT02766608","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2016-05-31","conditions":"Chronic Obstructive Pulmonary Disorder","enrollment":2389},{"nctId":"NCT00291408","phase":"PHASE4","title":"Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2006-04","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Age Matched Healthy Volunteers (Non-smokers)","enrollment":""},{"nctId":"NCT02546297","phase":"PHASE4","title":"Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2017-09-15","conditions":"COPD, Bronchiectasis","enrollment":90},{"nctId":"NCT02477397","phase":"PHASE3","title":"Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2015-05-01","conditions":"COPD","enrollment":201},{"nctId":"NCT01415518","phase":"PHASE4","title":"Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-09-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":581},{"nctId":"NCT00996697","phase":"PHASE4","title":"Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2006-10","conditions":"COPD","enrollment":23},{"nctId":"NCT02864342","phase":"PHASE4","title":"Adherence Study in COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-08-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD","enrollment":138},{"nctId":"NCT01099722","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2010-04","conditions":"Asthma","enrollment":261},{"nctId":"NCT02934607","phase":"PHASE1","title":"A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-11-04","conditions":"Study is Being Conducted in Healthy Volunteers","enrollment":50},{"nctId":"NCT02533505","phase":"PHASE4","title":"Phase IV O2 Consumption Study in COPD Patients.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-25","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":51},{"nctId":"NCT02345161","phase":"PHASE3","title":"A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1811}],"_emaApprovals":[],"_faersSignals":[{"count":17913,"reaction":"DYSPNOEA"},{"count":12043,"reaction":"ASTHMA"},{"count":7846,"reaction":"COUGH"},{"count":6767,"reaction":"DRUG INEFFECTIVE"},{"count":5973,"reaction":"OFF LABEL USE"},{"count":5804,"reaction":"PNEUMONIA"},{"count":5658,"reaction":"WHEEZING"},{"count":5377,"reaction":"FATIGUE"},{"count":4735,"reaction":"MALAISE"},{"count":4551,"reaction":"HEADACHE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL1370"},"formularyStatus":[],"_approvalHistory":[{"date":"20150414","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20140227","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20110818","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20171220","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20071026","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20071031","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20160610","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20120508","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20090227","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20080716","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20060721","type":"ORIG","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20140628","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20140404","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20140115","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20170911","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20110216","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20120723","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20100625","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"},{"date":"20170127","type":"SUPPL","sponsor":"ASTRAZENECA","applicationNumber":"NDA021929"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":221,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Symbicort","genericName":"Symbicort","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":10,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:06:13.844416+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}